<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706004</url>
  </required_header>
  <id_info>
    <org_study_id>76992</org_study_id>
    <nct_id>NCT00706004</nct_id>
  </id_info>
  <brief_title>Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis</brief_title>
  <official_title>Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the short term safety and effectiveness of
      lubiprostone when used for constipation in adults with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) affects about 30,000 people in the United States. It is caused by an
      absent or dysfunctional protein called CF transmembrane conductance regulator (CFTR) which
      functions as a chloride channel. Lubiprostone is a medication indicated for constipation that
      activates type 2 chloride channels (ClC-2) and has the potential to be an effective treatment
      for constipation in adults with CF. It has the potential to correct the underlying disorder
      by utilizing a chloride channel whose activity does not depend on CFTR. This project is a
      prospective open-label pilot study to examine the safety and effectiveness of lubiprostone
      when used in adults with CF with constipation. The specific aims are as follows: 1) Determine
      the effectiveness of lubiprostone for constipation in participants with CF, and 2) Determine
      the short term safety of lubiprostone in adults with CF. Data will also be collected to
      generate further information about the effect of lubiprostone on nutritional status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Spontaneous Bowel Movements Per Week</measure>
    <time_frame>2-week run-in period, 2-weeks of treatment, 4-weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptoms</measure>
    <time_frame>2-week run-in period, 2 weeks of treatment, 4 weeks of treatment</time_frame>
    <description>The Patient Assessment of Constipation - Symptom (PAC-SYM) survey is a 1-page 12-item tool that measures a patient's assessment of constipation symptoms. The items are in Likert scale format and address the severity of stool, rectal and abdominal symptoms over the past 2 weeks. Items are scored on a scale of 0 to 4, with 4 indicating the most severe. To compute the overall score, the scores of the non-missing items are summed and this is divided by the total number of non-missing items (overall score range, 0 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Scale Score</measure>
    <time_frame>2-week run-in period, 2 weeks of treatment, 4 weeks of treatment</time_frame>
    <description>The Bristol Stool Scale is a scale used to rate the consistency of stool. Stool types are accompanied by a written description. There are seven types of stool that are scored from 1 to 7. A score of 1 or 2 indicates constipation; a score of 6 or 7, diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>baseline, 2 weeks of treatment, 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Reported Adverse Effects at Each Study Visit</measure>
    <time_frame>During entire study period</time_frame>
    <description>Adverse effects are problems reported by each study subject that they experienced during this clinical trial. Examples are headache and nausea. Study subjects were asked at each visit while on study drug to report any adverse affects that had occurred since the last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sodium</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Chloride</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bicarb</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BUN</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Magnesium</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glucose</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vitamin D</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vitamin A</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vitamin E</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Prealbumin</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albumin</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Constipation</condition>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lubiprostone</intervention_name>
    <description>lubiprostone 24 microgram capsule taken twice daily for 4 weeks</description>
    <other_name>Brand name: Amitiza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women of all races

          -  18 years of age or older at time of enrollment

          -  Diagnosis of cystic fibrosis

          -  History of constipation, as defined by the Rome III criteria, OR the requirement of
             chronic scheduled doses of a laxative, OR a score ≥1.5 on the Patient assessment of
             constipation symptoms (PAC-SYM)15 survey administered during the screening visit, OR a
             score of less than 3 on the Bristol Stool Scale (BSS) at the screening visit.

        Exclusion Criteria:

          -  Current gastrointestinal (GI) obstruction

          -  History of GI obstruction requiring hospitalization within six months of enrollment

          -  Pregnancy or breastfeeding

          -  Hypersensitivity to lubiprostone or any of its components

          -  Serum creatinine &gt;1.8 mg/dL at last annual visit

          -  Clinically significant liver disease, defined as aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) &gt;3X upper limit of normal

          -  History of frequent hospital admissions for CF exacerbations (≥4 in the last 6 months)

          -  Currently registered on a lung transplant waiting list

          -  Women of capable of child-bearing who either refuse a pregnancy test, or are incapable
             or unwilling to use contraception during the protocol, or both.

          -  Any other condition, in the opinion of the investigators, that interferes with the
             ability of the participant to comply with study requirements, confers significant risk
             to the participant, or limits the ability of the participant to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine E. O'Brien, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <results_first_submitted>February 16, 2011</results_first_submitted>
  <results_first_submitted_qc>March 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Catherine E. O'Brien</name_title>
    <organization>University of Arkansas for Medical Sciences</organization>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>lubiprostone</keyword>
  <keyword>Constipation in adults with cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone</title>
          <description>24 micrograms twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone</title>
          <description>24 micrograms twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The number of subjects analyzed here is 7 as only 7 completed this pilot study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>The number of subjects analyzed here is 7 as only 7 completed this pilot study.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The number of subjects analyzed here is 7 as only 7 completed this pilot study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The number of subjects analyzed here is 7 as only 7 completed this pilot study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Spontaneous Bowel Movements Per Week</title>
        <time_frame>2-week run-in period, 2-weeks of treatment, 4-weeks of treatment</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Spontaneous Bowel Movements Per Week</title>
          <population>Participants who completed the study</population>
          <units>bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Constipation Symptoms</title>
        <description>The Patient Assessment of Constipation – Symptom (PAC-SYM) survey is a 1-page 12-item tool that measures a patient’s assessment of constipation symptoms. The items are in Likert scale format and address the severity of stool, rectal and abdominal symptoms over the past 2 weeks. Items are scored on a scale of 0 to 4, with 4 indicating the most severe. To compute the overall score, the scores of the non-missing items are summed and this is divided by the total number of non-missing items (overall score range, 0 to 4).</description>
        <time_frame>2-week run-in period, 2 weeks of treatment, 4 weeks of treatment</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Constipation Symptoms</title>
          <description>The Patient Assessment of Constipation – Symptom (PAC-SYM) survey is a 1-page 12-item tool that measures a patient’s assessment of constipation symptoms. The items are in Likert scale format and address the severity of stool, rectal and abdominal symptoms over the past 2 weeks. Items are scored on a scale of 0 to 4, with 4 indicating the most severe. To compute the overall score, the scores of the non-missing items are summed and this is divided by the total number of non-missing items (overall score range, 0 to 4).</description>
          <population>Participants who completed the study</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bristol Stool Scale Score</title>
        <description>The Bristol Stool Scale is a scale used to rate the consistency of stool. Stool types are accompanied by a written description. There are seven types of stool that are scored from 1 to 7. A score of 1 or 2 indicates constipation; a score of 6 or 7, diarrhea.</description>
        <time_frame>2-week run-in period, 2 weeks of treatment, 4 weeks of treatment</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Bristol Stool Scale Score</title>
          <description>The Bristol Stool Scale is a scale used to rate the consistency of stool. Stool types are accompanied by a written description. There are seven types of stool that are scored from 1 to 7. A score of 1 or 2 indicates constipation; a score of 6 or 7, diarrhea.</description>
          <population>Participants who completed the study</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <time_frame>baseline, 2 weeks of treatment, 4 weeks of treatment</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <population>Participants who completed the study</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self Reported Adverse Effects at Each Study Visit</title>
        <description>Adverse effects are problems reported by each study subject that they experienced during this clinical trial. Examples are headache and nausea. Study subjects were asked at each visit while on study drug to report any adverse affects that had occurred since the last visit.</description>
        <time_frame>During entire study period</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Self Reported Adverse Effects at Each Study Visit</title>
          <description>Adverse effects are problems reported by each study subject that they experienced during this clinical trial. Examples are headache and nausea. Study subjects were asked at each visit while on study drug to report any adverse affects that had occurred since the last visit.</description>
          <population>Participants who completed the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Sodium</title>
        <time_frame>baseline, 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Sodium</title>
          <population>Participants who completed the study</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Chloride</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Chloride</title>
          <population>Participants who completed the study</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Potassium</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium</title>
          <population>Participants who completed the study</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bicarb</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bicarb</title>
          <population>Participants who completed the study</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BUN</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BUN</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>AST</title>
          <population>Participants who completed the study</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>ALT</title>
          <population>Participants who completed the study</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Magnesium</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Magnesium</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Phosphate</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Phosphate</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Glucose</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glucose</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.3" spread="101.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" spread="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Vitamin D</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Vitamin D</title>
          <population>Participants who completed the study</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Vitamin A</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Vitamin A</title>
          <population>Participants who completed the study</population>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Vitamin E</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Vitamin E</title>
          <population>Participants who completed the study</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Prealbumin</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Prealbumin</title>
          <population>Participants who completed the study</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Albumin</title>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24 Mcg Twice Daily</title>
            <description>Participants served as their own controls</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Albumin</title>
          <population>Participants who completed the study</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone</title>
          <description>24 micrograms twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Transient chest tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Catherine O'Brien</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-364-1828</phone>
      <email>obriencatherinee@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

